In the largest and most recent of these, 51 patients with warm or cold-antibody AIHA and reduced EPO levels or inadequate EPO response had been treated with an ESA, starting at median 24 months after diagnosis (103). The gene discussed is EPO; the disease is autoimmune hemolytic anemia.